Skip to main navigation Skip to search Skip to main content

Contemporary management of advanced prostate cancer: An evolving landscape

  • Abhinav Khanna
  • , Luke P. O’Connor
  • , Prithvi B. Murthy
  • , Darren J. Bryk
  • , Michele Fascelli
  • , Kyle Ericson
  • , Nitin K. Yerram
  • , Samuel C. Haywood
  • , Robert Abouassaly
  • Cleveland Clinic Foundation

Research output: Contribution to journal › Article › peer-review

Abstract

Recent population-based studies suggest that the incidence of advanced and metastatic prostate cancer may be increasing. Concurrently with this apparent stage migration toward advanced disease, several major developments have occurred in the treatment paradigm for men with advanced prostate cancer. These include the US Food and Drug Administration approval of 8 novel agents over the last decade. In addition to novel pharmaceuticals, rapidly evolving diagnostic tools have emerged. This review provides a primer for clinicians who treat men with advanced prostate cancer, including medical oncologists, radiation oncologists, and urologists.

Original languageEnglish
Pages (from-to)108-118
Number of pages11
JournalClinical Advances in Hematology and Oncology
Volume19
Issue number2
StatePublished - Feb 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Advanced prostate cancer
  • Anti-androgen
  • Castration- resistant
  • Castration-sensitive
  • Prostate cancer
  • Prostate-specific membrane antigen

Fingerprint

Dive into the research topics of 'Contemporary management of advanced prostate cancer: An evolving landscape'. Together they form a unique fingerprint.

Cite this